Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Jing Deng, Shuyan Gu, Hui Shao, Hengjin Dong, Dajin Zou & Lizheng Shi. (2015) Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. Journal of Medical Economics 18:11, pages 974-989.
Read now
Read now
Pernilla Huetson, James L. Palmer, Andrée Levorsen, Marie Fournier, Maeva Germe & Euan McLeod. (2015) Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. Journal of Medical Economics 18:8, pages 573-585.
Read now
Read now
Victoria K. Brennan, Ann D. Colosia, Catherine Copley-Merriman, Josephine Mauskopf, Bastian Hass & Roberto Palencia. (2014) Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. Journal of Medical Economics 17:7, pages 469-480.
Read now
Read now
Urpo Kiiskinen, Stephan Matthaei, Matthew Reaney, Chantal Mathieu, Claes-Göran Östenson, Thure Krarup, Michael Theodorakis, Jacek Kiljański, Carole Salaun-Martin, Hélène Sapin & Bruno Guerci. (2013) Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study. ClinicoEconomics and Outcomes Research 5, pages 355-367.
Read now
Read now
R. F. Pollock, J. Chilcott, G. Muduma & W. J. Valentine. (2013) Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics 16:2, pages 249-259.
Read now
Read now
Amélie Beaudet, James L. Palmer, Louise Timlin, Bernard Wilson, David Bruhn, Kristina S. Boye & Adam Lloyd. (2011) Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. Journal of Medical Economics 14:3, pages 357-366.
Read now
Read now
Manjiri Pawaskar, Anthony Zagar, Tomoko Sugihara & Lizheng Shi. (2011) Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. Journal of Medical Economics 14:1, pages 16-27.
Read now
Read now
Y. Yi, Z. Philips, G. Bergman & K. Burslem. (2010) Economic models in type 2 diabetes. Current Medical Research and Opinion 26:9, pages 2105-2118.
Read now
Read now
Joan Khoo, Christopher K Rayner, Karen L Jones & Michael Horowitz. (2009) Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Therapeutics and Clinical Risk Management 5, pages 683-698.
Read now
Read now
Stanislav Goykhman, Andjela Drincic, Jean Claude Desmangles & Marc Rendell. (2009) Insulin Glargine: a review 8 years after its introduction. Expert Opinion on Pharmacotherapy 10:4, pages 705-718.
Read now
Read now
Articles from other publishers (35)
Chun-Ting Yang, Wen-Yu Yao, Huang-Tz Ou & Shihchen Kuo. (2023) Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data. Diabetes Research and Clinical Practice 198, pages 110625.
Crossref
Crossref
Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou & Shihchen Kuo. (2021) Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Evan W. Davies & Rosirene Paczkowski. (2017) Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Services Research 17:1.
Crossref
Crossref
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang & Hengjin Dong. (2017) Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes, Obesity and Metabolism 19:12, pages 1688-1697.
Crossref
Crossref
Sarah E. Holden, Christopher Ll. Morgan, Qing Qiao, Sara Jenkins-Jones, Ellen R. Berni & Craig J. Currie. (2017) Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. Diabetes, Obesity and Metabolism 19:8, pages 1097-1105.
Crossref
Crossref
Kurt Fortwaengler, Christopher G. Parkin, Kurt Neeser, Monika Neumann & Oliver Mast. (2016) Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c). Journal of Diabetes Science and Technology 11:2, pages 315-323.
Crossref
Crossref
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman & Philip Clarke. (2016) How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. PharmacoEconomics 35:3, pages 319-329.
Crossref
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
Barnaby Hunt, Qing Ye, William J. Valentine & Donna Ashley. (2017) Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. Diabetes Therapy 8:1, pages 129-147.
Crossref
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Crossref
Carl V. Asche, Stephen E. Hippler & Dean T. Eurich. (2013) Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus. PharmacoEconomics 32:1, pages 15-27.
Crossref
Crossref
P Karagianni, SA Polyzos, N Kartali, I Zografou & C Sambanis. (2013) Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. Advances in Medical Sciences 58:1, pages 38-43.
Crossref
Crossref
R. F. Pollock, G. Muduma & W. J. Valentine. (2012)
Evaluating the cost‐effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the
UK
. Diabetes, Obesity and Metabolism 15:2, pages 121-129.
Crossref
Crossref
Richard F. Pollock, Bradley H. Curtis, Jayne Smith-Palmer & William J. Valentine. (2012) A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy 29:12, pages 1051-1066.
Crossref
Crossref
Dhanwantee Mundil, Alison Cameron-Vendrig & Mansoor Husain. (2012) GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. Diabetes and Vascular Disease Research 9:2, pages 95-108.
Crossref
Crossref
Roger S. Mazze, Ellie S. Strock, Richard M. Bergenstal, Amy Criego, Robert Cuddihy, Oded Langer, Gregg D. Simonson & Margaret A. Powers. 2011. Staged Diabetes Management. Staged Diabetes Management
77
137
.
William J. Valentine, Andrew J. Palmer, Morten Lammert, Jakob Langer & Michael Brändle. (2011) Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. Clinical Therapeutics 33:11, pages 1698-1712.
Crossref
Crossref
Gordon Goodall, María Costi, Louise Timlin, Jesús Reviriego, José Antonio Sacristán, Jayne Smith-Palmer & Tatiana Dilla. (2011) Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España. Endocrinología y Nutrición 58:7, pages 331-340.
Crossref
Crossref
Gordon Goodall, María Costi, Louise Timlin, Jesús Reviriego, José Antonio Sacristán, Jayne Smith-Palmer & Tatiana Dilla. (2011) Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition) 58:7, pages 331-340.
Crossref
Crossref
Daniel M.D. Tucker & Andrew J. Palmer. (2011) The cost-effectiveness of interventions in diabetes: A review of published economic evaluations in the UK setting, with an eye on the future. Primary Care Diabetes 5:1, pages 9-17.
Crossref
Crossref
Won Chan Lee, Christopher Conner & Mette Hammer. (2010) Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clinical Therapeutics 32:10, pages 1756-1767.
Crossref
Crossref
Wei-Xin Li, Jian-Feng Gou, Jin-Hui Tian, Xiang Yan & Lin Yang. (2010) Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Current Therapeutic Research 71:4, pages 211-238.
Crossref
Crossref
Davida F. Kruger, Bruce Bode & Geralyn R. Spollett. (2010) Understanding GLP-1 Analogs and Enhancing Patient Success. The Diabetes Educator 36:3_suppl, pages 44S-72S.
Crossref
Crossref
Anushua SinhaMangala RajanThomas HoergerLen Pogach. (2010) Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes. Diabetes Care 33:4, pages 695-700.
Crossref
Crossref
Derek Misurski, Maureen J. Lage, Rosalind Fabunmi & Kristina S. Boye. (2012) A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Applied Health Economics and Health Policy 7:4, pages 245-254.
Crossref
Crossref
T. Mittendorf, J. Smith-Palmer, L. Timlin, M. Happich & G. Goodall. (2009) Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes, Obesity and Metabolism 11:11, pages 1068-1079.
Crossref
Crossref
Irene A. Weiss, Guy Valiquette & Monica D. Schwarcz. (2009) Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes. Cardiology in Review 17:4, pages 165-175.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Crossref
P. Levin. (2008) The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics. Diabetes, Obesity and Metabolism 10:s2, pages 66-75.
Crossref
Crossref
R. Ravasio. (2013) Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale. Giornale Italiano di Health Technology Assessment 1:1, pages 21-30.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
Crossref
. (2013) Exenatide looks attractive in the UK setting. PharmacoEconomics & Outcomes News 529:1, pages 5-5.
Crossref
Crossref
Risto S Cvetkovi??Greg L Plosker. (2007) Exenatide. Drugs 67:6, pages 935-954.
Crossref
Crossref